BDR Pharma launches 80 mg version of prostate cancer drug at Rs 24,480 per pack in India

The company had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40 mg enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name Bdenza, BDR Pharma said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ci6t41
via IFTTT